HomeCompareSMNNY vs MRK

SMNNY vs MRK: Dividend Comparison 2026

SMNNY yields 1.42% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMNNY wins by $15.79M in total portfolio value· pulled ahead in Year 3
10 years
SMNNY
SMNNY
● Live price
1.42%
Share price
$10.52
Annual div
$0.15
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.85M
Annual income
$13,959,434.02
Full SMNNY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SMNNY vs MRK

📍 SMNNY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMNNYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMNNY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMNNY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMNNY
Annual income on $10K today (after 15% tax)
$120.49/yr
After 10yr DRIP, annual income (after tax)
$11,865,518.92/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SMNNY beats the other by $11,857,190.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMNNY + MRK for your $10,000?

SMNNY: 50%MRK: 50%
100% MRK50/50100% SMNNY
Portfolio after 10yr
$7.95M
Annual income
$6,984,616.08/yr
Blended yield
87.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SMNNY
No analyst data
Altman Z
14.6
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMNNY buys
0
MRK buys
0
No recent congressional trades found for SMNNY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMNNYMRK
Forward yield1.42%2.76%
Annual dividend / share$0.15$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$15.85M$56.8K
Annual income after 10y$13,959,434.02$9,798.13
Total dividends collected$15.68M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMNNY vs MRK ($10,000, DRIP)

YearSMNNY PortfolioSMNNY Income/yrMRK PortfolioMRK Income/yrGap
1$10,984$283.52$11,206$366.19$222.00MRK
2$12,334$582.06$12,650$502.35$316.00MRK
3← crossover$14,420$1,221.77$14,407$694.19+$13.00SMNNY
4$18,099$2,669.75$16,585$967.82+$1.5KSMNNY
5$25,629$6,263.43$19,342$1,363.89+$6.3KSMNNY
6$44,002$16,578.42$22,913$1,947.19+$21.1KSMNNY
7$100,283$53,201.56$27,662$2,823.89+$72.6KSMNNY
8$333,940$226,637.10$34,159$4,173.35+$299.8KSMNNY
9$1,767,961$1,410,644.64$43,337$6,308.80+$1.72MSMNNY
10$15,851,152$13,959,434.02$56,776$9,798.13+$15.79MSMNNY

SMNNY vs MRK: Complete Analysis 2026

SMNNYStock

Shimano Inc. develops, produces, and distributes bicycle components, fishing tackles, and rowing equipment. The company also plans and develops lifestyle gear products, such as apparel items, shoes, bags, and related items. It has operations in Japan, Asia, Europe, North America, Latin America, and Oceania. The company was founded in 1921 and is headquartered in Sakai, Japan.

Full SMNNY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SMNNY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMNNY vs SCHDSMNNY vs JEPISMNNY vs OSMNNY vs KOSMNNY vs MAINSMNNY vs JNJSMNNY vs ABBVSMNNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.